Skip to navigation | Skip to main content | Skip to footer
Menu
Search the University of Manchester siteSearch Menu StaffNet

eHealth webinar on improving the monitoring of drugs for safety

29 Mar 2012

On 3 April (12.30pm) in Room 1.10 Kilburn Building The Observational Medical Outcomes Partnership will be conducting a webinar for all interested University of Manchester staff to join.

If you are unable to join us for the group dial-in, please feel free to log in:

The Observational Medical Outcomes Partnership (OMOP) is a public-private partnership between the US FDA, the Foundation for the National Institutes of Health (FNIH), the Pharmaceutical Research and Manufacturers Association, data owners, and academia.

OMOP is designed to help improve the monitoring of drugs for safety. The partnership is conducting a multi-year initiative to research methods that are feasible and useful to analyze existing healthcare databases to identify and evaluate safety and benefit issues of drugs already on the market. Utilizing databases of patient medical records and administrative claims, researchers are developing and testing various analytical methods for their ability to detect and evaluate drug safety issues over time. OMOP promotes transparency by placing all information of interest in the public domain as quickly as possible:

They will discuss an overview of the first three years of OMOP research activities including the infrastructure/tools, methods, and initial results.

Additional information can be found in: